Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
Open Access
- 19 May 2021
- journal article
- research article
- Published by Springer Nature in Targeted Oncology
- Vol. 16 (4) , 435-446
Abstract
Background Esophageal adenocarcinoma patients have limited treatment options. TGF-β can be upregulated in esophageal adenocarcinoma, and blocking this pathway may enhance clinical response to PD-(L)1 inhibitors. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1. Objective The objective of this study was to investigate the efficacy and safety of bintrafusp alfa in patients with advanced, post-platinum esophageal adenocarcinoma, unselected for PD-L1 expression. Patients and Methods In this phase 1 study, patients with post-platinum, PD-L1–unselected esophageal adenocarcinoma received bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was confirmed best overall response per RECIST 1.1 by independent review committee (IRC). Results By the database cutoff of 24 August 2018, 30 patients (80.0% had two or more prior anticancer regimens) received bintrafusp alfa for a median of 6.1 weeks. The confirmed objective response rate (ORR) per IRC was 20.0% (95% CI 7.7–38.6); responses lasted 1.3–8.3 months. Most responses (83.3%) occurred in tumors with an immune-excluded phenotype. Investigator-assessed confirmed ORR was 13.3% (95% CI 3.8–30.7). Nineteen patients (63.3%) had treatment-related adverse events: seven patients (23.3%) had grade 3 events; no grade 4 events or treatment-related deaths occurred. Conclusions Bintrafusp alfa showed signs of clinical efficacy with a manageable safety profile in patients with heavily pretreated, advanced esophageal adenocarcinoma. Clinical Trials Registration NCT02517398.Keywords
Funding Information
- Merck KGaA
- GlaxoSmithKline
This publication has 47 references indexed in Scilit:
- TGF- : Duality of Function Between Tumor Prevention and CarcinogenesisJNCI: Journal of the National Cancer Institute, 2014
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Targeting the TGFβ signalling pathway in diseaseNature Reviews Drug Discovery, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Transforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor MicroenvironmentGastroenterology, 2011
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genomeBMC Bioinformatics, 2011
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal AdenocarcinomaClinical Cancer Research, 2010
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- In vivo and In vitro Evidence for Transforming Growth Factor-β1-Mediated Epithelial to Mesenchymal Transition in Esophageal AdenocarcinomaCancer Research, 2006
- Overexpression of TGF‐β1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosisMolecular Carcinogenesis, 2006